MX2012004089A - Inhibidores de hsp90. - Google Patents
Inhibidores de hsp90.Info
- Publication number
- MX2012004089A MX2012004089A MX2012004089A MX2012004089A MX2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- purine derivatives
- derivatives useful
- hsp90 inhibitors
- hsp90
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title abstract 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title abstract 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud proporciona los derivados de purina sustituidos y los compuestos relacionados de las fórmulas mostradas. Estos compuestos son útiles como inhibidores de HSP90, y por lo tanto, en el tratamiento de las enfermedades relacionadas. (Fórmulas) Z1-Z3, Xa-XC, X2, X4, Y y R son según lo definido en la especificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24934909P | 2009-10-07 | 2009-10-07 | |
| PCT/US2010/051872 WO2011044394A1 (en) | 2009-10-07 | 2010-10-07 | Purine derivatives useful as hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012004089A true MX2012004089A (es) | 2012-08-23 |
| MX340714B MX340714B (es) | 2016-07-22 |
Family
ID=43857159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004089A MX340714B (es) | 2009-10-07 | 2010-10-07 | Inhibidores de hsp90. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9328114B2 (es) |
| EP (2) | EP2486039B1 (es) |
| JP (3) | JP5941407B2 (es) |
| KR (2) | KR101906568B1 (es) |
| CN (3) | CN102639534A (es) |
| AU (1) | AU2010303343B2 (es) |
| BR (1) | BR112012008019A2 (es) |
| CA (1) | CA2776308C (es) |
| DK (1) | DK2486039T3 (es) |
| EA (1) | EA029272B1 (es) |
| ES (2) | ES2589403T3 (es) |
| LT (1) | LT2486039T (es) |
| MX (1) | MX340714B (es) |
| NZ (2) | NZ625593A (es) |
| PT (1) | PT2486039T (es) |
| WO (1) | WO2011044394A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| BR112012008019A2 (pt) | 2009-10-07 | 2016-03-01 | Sloan Kettering Inst Cancer | derivados de purina úteis como inibidores de hsp90 |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| BR112013025634A2 (pt) | 2011-04-05 | 2016-07-19 | Sloan Kettering Inst Cancer | inibidores de hsp90 |
| AU2012282903A1 (en) | 2011-07-08 | 2014-02-13 | Sloan-Kettering Institute For Cancer Research | Uses of labeled HSP90 inhibitors |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| EA201690406A1 (ru) | 2013-08-16 | 2016-08-31 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Селективные ингибиторы grp94 и способы их применения |
| CA2921410C (en) | 2013-08-23 | 2023-03-28 | Neupharma, Inc. | Quinazoline derivatives, compositions and their use as kinase inhibitors |
| KR102325454B1 (ko) | 2013-12-23 | 2021-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | 방사성표지화를 위한 방법 및 시약 |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| AU2016336351A1 (en) | 2015-10-05 | 2018-05-10 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| EP3497087B1 (en) | 2016-08-15 | 2021-11-10 | Neupharma, Inc. | Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| CA3061185A1 (en) * | 2017-04-24 | 2018-11-01 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
| AU2018290288A1 (en) * | 2017-06-23 | 2020-01-16 | Samus Therapeutics, Inc. | Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025099111A1 (en) | 2023-11-10 | 2025-05-15 | Wella Germany Gmbh | New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol) |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903922B2 (ja) | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| AU2877102A (en) | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Small molecule compositions for binding to hsp90 |
| NL1019258C2 (nl) * | 2001-10-30 | 2003-05-02 | Iku Holding Montfoort Bv | Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig. |
| US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| AU2002356922A1 (en) | 2001-11-09 | 2003-05-26 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| RU2004129276A (ru) | 2002-02-28 | 2005-06-10 | Астразенека Аб (Se) | Производные 3-циклического-5-(азотсодержащего 5-членного кольцевого) метил-оксазолидинона и их применение в качестве антибактериальных средств |
| US7592143B2 (en) | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| EP1913738A2 (en) | 2005-07-27 | 2008-04-23 | QUALCOMM Incorporated | System and method for forward link only messages |
| NZ572600A (en) * | 2006-05-12 | 2011-08-26 | Myrexis Inc | 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders |
| WO2007143629A1 (en) | 2006-06-02 | 2007-12-13 | Nexgenix Pharmaceuticals | Treatment of neurofibromatosis with inhibitors of a signal transduction pathway |
| WO2008005937A2 (en) | 2006-06-30 | 2008-01-10 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibiton of hsp90 |
| US20080053862A1 (en) | 2006-06-30 | 2008-03-06 | Sanford, L.P. | Interlocking Nestable Article Holder |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| SI2069324T1 (sl) | 2007-03-20 | 2013-10-30 | Curis, Inc. | Kondenzirani aminopiridini kot HSP90-inhibitorji |
| US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| WO2009007399A1 (en) | 2007-07-12 | 2009-01-15 | Crystax Pharmaceuticals, S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| NZ586129A (en) * | 2007-11-14 | 2012-06-29 | Myrexis Inc | Therapeutic compounds and their use in treating diseases and disorders |
| BR112012008019A2 (pt) | 2009-10-07 | 2016-03-01 | Sloan Kettering Inst Cancer | derivados de purina úteis como inibidores de hsp90 |
| BR112013025634A2 (pt) | 2011-04-05 | 2016-07-19 | Sloan Kettering Inst Cancer | inibidores de hsp90 |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| EA201690406A1 (ru) | 2013-08-16 | 2016-08-31 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Селективные ингибиторы grp94 и способы их применения |
-
2010
- 2010-10-07 BR BR112012008019A patent/BR112012008019A2/pt not_active IP Right Cessation
- 2010-10-07 ES ES10822718.2T patent/ES2589403T3/es active Active
- 2010-10-07 MX MX2012004089A patent/MX340714B/es active IP Right Grant
- 2010-10-07 US US13/500,809 patent/US9328114B2/en active Active
- 2010-10-07 CN CN201080055473.1A patent/CN102639534A/zh active Pending
- 2010-10-07 JP JP2012533327A patent/JP5941407B2/ja not_active Expired - Fee Related
- 2010-10-07 AU AU2010303343A patent/AU2010303343B2/en not_active Ceased
- 2010-10-07 KR KR1020127011546A patent/KR101906568B1/ko not_active Expired - Fee Related
- 2010-10-07 LT LTEP10822718.2T patent/LT2486039T/lt unknown
- 2010-10-07 KR KR1020187028594A patent/KR102129420B1/ko not_active Expired - Fee Related
- 2010-10-07 EP EP10822718.2A patent/EP2486039B1/en active Active
- 2010-10-07 WO PCT/US2010/051872 patent/WO2011044394A1/en not_active Ceased
- 2010-10-07 CA CA2776308A patent/CA2776308C/en not_active Expired - Fee Related
- 2010-10-07 NZ NZ625593A patent/NZ625593A/en not_active IP Right Cessation
- 2010-10-07 ES ES16171952T patent/ES2733131T3/es active Active
- 2010-10-07 CN CN201610270112.8A patent/CN105924443A/zh active Pending
- 2010-10-07 EP EP16171952.1A patent/EP3091019B1/en not_active Not-in-force
- 2010-10-07 DK DK10822718.2T patent/DK2486039T3/en active
- 2010-10-07 PT PT108227182T patent/PT2486039T/pt unknown
- 2010-10-07 CN CN201610269904.3A patent/CN106083855B/zh not_active Expired - Fee Related
- 2010-10-07 EA EA201270535A patent/EA029272B1/ru not_active IP Right Cessation
- 2010-10-07 NZ NZ599138A patent/NZ599138A/en not_active IP Right Cessation
-
2016
- 2016-04-21 US US15/135,121 patent/US10172863B2/en active Active
- 2016-05-20 JP JP2016101964A patent/JP6326088B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-15 JP JP2018024710A patent/JP6804483B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012004089A (es) | Inhibidores de hsp90. | |
| MX2010003155A (es) | Derivados de ciclopropil aril amida y uso de los mismos. | |
| MX2012008049A (es) | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. | |
| TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MX2009008798A (es) | Derivados de iminipiridina y sus usos como microbicidas. | |
| MX2009010595A (es) | Derivados de pirrolopirimidina. | |
| TW200833675A (en) | Nicotinamide derivatives | |
| TN2010000167A1 (en) | Organic compounds | |
| PT2421879E (pt) | Novos 7-deazapurina nucleósidos para utilizações terapêuticas | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| WO2008152014A3 (en) | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases | |
| TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
| IL192253A0 (en) | Substituted cyclohexylmethyl derivatives | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| IN2012DN03182A (es) | ||
| TN2010000038A1 (en) | Organic compounds | |
| MX2009003081A (es) | Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas. | |
| UA99787C2 (en) | Lactams as beta secretase inhibitors | |
| MX2010006108A (es) | Inhibidores de estearoil-coa-desaturasa. | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| MY152030A (en) | Novel herbicides | |
| TW200630374A (en) | Thiazolyldihydroindazoles | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| TW200745066A (en) | Novel PTP1B inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |